MMRF Molecular Profiling Protocol
Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies
1 other identifier
observational
1,000
2 countries
20
Brief Summary
This protocol is now being used as screening for the MyDRUG study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2015
Longer than P75 for all trials
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2015
CompletedFirst Submitted
Initial submission to the registry
August 25, 2016
CompletedFirst Posted
Study publicly available on registry
August 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
May 6, 2025
February 1, 2023
11 years
August 25, 2016
May 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
actionable mutations report
10-14 days
Secondary Outcomes (2)
Survival Rates
Overall survival
Disease Recurrence
Time to Progression
Interventions
Eligibility Criteria
patients with multiple myeloma and other related disorders including, without limitation to, smoldering myeloma, monoclonal gammopathy of undetermined significance (MGUS), primary plasma cell leukemia, solitary plasmacytoma, and amyloidosis
You may qualify if:
- Patients must have a diagnosis of multiple myeloma or related malignancy
- Patients are undergoing standard of care bone marrow aspirates
- Patients (male or female) from any race or ethnicity must be at least 18 years of age at the time of registration.
- Procedure-specific signed informed consent form prior to initiation of any study-related procedures.
You may not qualify if:
- It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo a bone marrow aspirate.
- Patients who are incarcerated are not eligible to participate.
- Women who are pregnant
- Patients who have had another malignancy within the last five (5) years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) where there is a possibility to contaminate the bone marrow aspirate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Mayo Clinic - Scottsdale
Scottsdale, Arizona, 85259, United States
City of Hope
Duarte, California, 91010, United States
UCSF Medical Center
San Francisco, California, 94143, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224, United States
Emory University
Atlanta, Georgia, 30322, United States
University of Chicago
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
Washington University
St Louis, Missouri, 63110, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Mount Sinai Medical Center
New York, New York, 10029, United States
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Ohio State University
Columbus, Ohio, 43210, United States
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
Baylor Research Institute
Dallas, Texas, 75246, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
Biospecimen
bone marrow and peripheral blood samples will be obtained
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Leif Bergsagel, M.D.
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2016
First Posted
August 30, 2016
Study Start
June 1, 2015
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Last Updated
May 6, 2025
Record last verified: 2023-02